JP2025509564A5 - - Google Patents

Info

Publication number
JP2025509564A5
JP2025509564A5 JP2024554777A JP2024554777A JP2025509564A5 JP 2025509564 A5 JP2025509564 A5 JP 2025509564A5 JP 2024554777 A JP2024554777 A JP 2024554777A JP 2024554777 A JP2024554777 A JP 2024554777A JP 2025509564 A5 JP2025509564 A5 JP 2025509564A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
nmod
adc
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/052428 external-priority patent/WO2023175483A1/en
Publication of JP2025509564A publication Critical patent/JP2025509564A/ja
Publication of JP2025509564A5 publication Critical patent/JP2025509564A5/ja
Pending legal-status Critical Current

Links

JP2024554777A 2022-03-16 2023-03-14 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法 Pending JP2025509564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320629P 2022-03-16 2022-03-16
US63/320,629 2022-03-16
PCT/IB2023/052428 WO2023175483A1 (en) 2022-03-16 2023-03-14 A scoring method for an anti-trop2 antibody‑drug conjugate therapy

Publications (2)

Publication Number Publication Date
JP2025509564A JP2025509564A (ja) 2025-04-11
JP2025509564A5 true JP2025509564A5 (cg-RX-API-DMAC7.html) 2026-03-19

Family

ID=85776040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554777A Pending JP2025509564A (ja) 2022-03-16 2023-03-14 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法

Country Status (8)

Country Link
EP (1) EP4493933A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509564A (cg-RX-API-DMAC7.html)
KR (1) KR20240165390A (cg-RX-API-DMAC7.html)
CN (1) CN118891525A (cg-RX-API-DMAC7.html)
AU (1) AU2023235490A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255700A1 (cg-RX-API-DMAC7.html)
IL (1) IL315662A (cg-RX-API-DMAC7.html)
WO (1) WO2023175483A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202619750A (zh) 2024-09-06 2026-05-16 英商阿斯特捷利康英國股份有限公司 抗trop2抗體-藥物結合物療法之評分方法
CN119986001B (zh) * 2025-01-23 2026-04-07 中山大学孙逸仙纪念医院 试剂盒及其在预测trop2-adc疗效中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
ITCH20120008A1 (it) * 2012-05-16 2013-11-17 Saverio Alberti Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
US10241115B2 (en) * 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
PT3313443T (pt) * 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CN108601841A (zh) * 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
ES2885178T3 (es) * 2017-02-06 2021-12-13 Novartis Ag Método para la predicción de respuesta a la inmunoterapia
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate

Similar Documents

Publication Publication Date Title
TWI847992B (zh) 抗體-藥物結合物之有效的製造方法
US20260139074A1 (en) Combination of antibody-drug conjugate and tubulin inhibitor
JP2023545359A5 (cg-RX-API-DMAC7.html)
JP2023539715A5 (cg-RX-API-DMAC7.html)
CN113271942A (zh) 抗体-药物缀合物与parp抑制剂的组合
TW201818973A (zh) 利用投予抗her2抗體-藥物結合物之抗性癌的治療
JP2019500020A5 (cg-RX-API-DMAC7.html)
TWI822822B (zh) 抗體-藥物結合物之用途
RU2009115363A (ru) Антагонисты рецепторов для лечения метастатического рака
WO2016145536A1 (en) Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
JP2023545096A5 (cg-RX-API-DMAC7.html)
JP7105304B2 (ja) 尿路上皮がんの治療における抗her2抗体-薬物コンジュゲートの使用
JP2024545428A5 (cg-RX-API-DMAC7.html)
RU2013123792A (ru) Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний
JP2019524706A5 (cg-RX-API-DMAC7.html)
JPWO2021251459A5 (cg-RX-API-DMAC7.html)
CN118891525A (zh) 用于抗trop2抗体-药物缀合物疗法的评分方法
TW201708407A (zh) 螢光綴合物
TW202500194A (zh) 用於癌症治療中患者選擇之CEACAM5 mRNA分析
JP2025503511A5 (cg-RX-API-DMAC7.html)
US20250276079A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR
JPWO2022019259A5 (cg-RX-API-DMAC7.html)
WO2025055589A1 (en) Methods of treating cervical cancer using anti-her2 antibody-drug conjugates
CN113754764B (zh) 抗dog-1抗体、缀合物、药物组合物、药物制剂及其用途
CN120053679A (zh) 一种靶向CD66c的抗体偶联药物及其在制备胃食管结合部癌治疗药物中的用途